QDX Hails Co-Founder and Chief Researcher Giuseppe Barca on Earning the Prestigious 2025 Dirac Medal

PRNewswire

Singapore, May 8: QDX proudly congratulates its Co-Founder and Head of Research, A/Prof. Giuseppe Barca, on being awarded the 2025 Dirac Medal, the highest international honour for early-career researchers in theoretical and
computational chemistry
.

Presented by the World Association of Theoretical and Computational Chemists (WATOC), the Dirac Medal recognises scientists under 40 whose research has made exceptional contributions to the field. A/Prof. Barca is recognised for his pioneering work in quantum algorithms and high-performance computing, which has advanced the frontiers of molecular simulation and accelerated applications in
drug discovery
.

“This is a phenomenal and well-deserved honour for Giuseppe,” said Loong Wang, CEO of QDX. “His research continues to redefine what’s possible in
computational chemistry
. This award not only celebrates his individual achievement but also reinforces the bold science that drives QDX.”

In addition to his role at QDX, A/Prof. Barca leads the Barca Lab at both the Australian National University and the University of Melbourne, where he develops fast, scalable quantum chemistry methods and algorithms for next-generation computing platforms. His innovations form the core of Rush, QDX’s proprietary AI-quantum platform designed to deliver high-precision molecular modelling at cloud scale.

As QDX continues to push the frontier of
drug discovery
with advanced computational tools, A/Prof. Barca’s vision and leadership remain central to its mission to enable and accelerate the discovery of new therapies.

About QDX

QDX is a
drug discovery
company specializing in high-performance quantum simulations to accelerate the design of new therapeutics. Founded by experts in
life science
,
computational chemistry
, and high-performance computing, QDX works alongside international partners to create groundbreaking solutions for intricate diseases, striving to revolutionize the medical field.
drug discovery
Its main offering, Rush, enables biotechnology pioneers to perform rapid, economical molecular modeling, virtual screenings, and predictive analysis—without needing any installations or specialized equipment.

Media Contact:

[email protected]

www.qdx.co

(ADVERTORIAL DISCLOSURE: The aforementioned press release has been supplied by
PRNewswire
ANI shall not bear any responsibility for the content thereof).